PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: IP
Does India's Glivec Decision Make April Fools of Us All?
By Helen Disney, Pugatch Consilium.
On April 1, India’s Supreme Court denied an appeal challenging the rejection of a patent for Novartis’s cancer drug, Glivec. The drug is a life-saving medicine for certain forms of cancer, patented in nearly 40 other countries — including many which are not noted for the strength of their intellectual property [...]
Global Patent Management Made Easy
Patent Management Made Easy
Even with a successfully launched start-up or spin-out to your name, you may still be tempted to close your eyes to the complexities of IP. But it’s actually very simple, writes Jason Rutt.
So, you have done it. You have left big business or forsaken the dusty halls of academia to launch that [...]
Posted in Europe, Global, Guest Blog, IP, Legal Also tagged Law, Patent, patent management Leave a comment
Fixing Innovation: Lilly's CEO Says Why, and How
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, IP, Legal, Market Access, Meetings, People, R&D, Regulatory, Safety, Strategy, Technology, healthcare, leadership, pricing Also tagged CEO, CEOs, drug safety, Eli Lilly, Financial Times, Global, healthcare reform, innovation, IPAB, Lilly, PhRMA, policy, R&D 1 Comment
It's Industry's Problem: A Fresh Take on R&D Costs
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty.
If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
Posted in Global, IP, R&D, leadership Also tagged Andrew Witty, GSK, lean management, R&D 2 Comments
PhRMA Dismayed by Global IPR Report